%0 Journal Article %T Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin %A Abdulgafoor Kassim %A Ramea Alathwary %A Talal Al-hogami %J Open Access Library Journal %V 6 %N 6 %P 1-9 %@ 2333-9721 %D 2019 %I Open Access Library %R 10.4236/oalib.1105507 %X
Objectives: To study the effectiveness and safety of ledipasvir-sofosbuvir plus ribavirin treatment in Yemeni patient with HCV infection. Design: Prospective study of sixty-five Yemeni patients confirmed with HCV infection during the period from January 2017 to April 2018. Setting: Gastrointestinal and liver diseases specialized center in Ibb city, Yemen. Subjects: Patients with proved HCV infection by PCR. Results: We collected 65 cases with HCV infection. They were 19 (29.2%) males and 46 (70.8) females with age ranged between 18 years and 70 years and the mean age was 47.98 ¡À 11.90 years. sixteen (24.6%) of them had compensated liver cirrhosis and the remainder were non-cirrhotic healthy individual. The early virological response reported in 100% of cases while the sustained virological response (SVR) reported in 90.8%. The reported side effects of our patients were fatigue in (24.6%), abdominal pain in (13.8%), diarrhea in (10.8%), insomnia in (9.2%), headache in (7.7%), and nausea/vomiting in (7.7%). Conclusion: The Sofosbuvir-ledipasvir plus Ribavirin treatment was highly effective and safe for the treatment of hepatitis C patients in Yemen.
%K HCV %K Early Virological Response (EVR) %K MPIVIROPACT Plus %K Yemen %U http://www.oalib.com/paper/5386363